WO2023200873A3 - Chimeric antigen receptor compositions and methods of using the same - Google Patents

Chimeric antigen receptor compositions and methods of using the same Download PDF

Info

Publication number
WO2023200873A3
WO2023200873A3 PCT/US2023/018345 US2023018345W WO2023200873A3 WO 2023200873 A3 WO2023200873 A3 WO 2023200873A3 US 2023018345 W US2023018345 W US 2023018345W WO 2023200873 A3 WO2023200873 A3 WO 2023200873A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen receptor
chimeric antigen
methods
same
mammal
Prior art date
Application number
PCT/US2023/018345
Other languages
French (fr)
Other versions
WO2023200873A2 (en
Inventor
John DIPERSIO
Julie O'NEAL
Julie RITCHEY
Ramzi ABBOUD
Original Assignee
Washington University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University filed Critical Washington University
Publication of WO2023200873A2 publication Critical patent/WO2023200873A2/en
Publication of WO2023200873A3 publication Critical patent/WO2023200873A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This application generally relates to immune cellular therapy. In particular, the disclosure relates to chimeric antigen receptor (CAR) constructs, cells comprising the same, and methods of treating subjects in need thereof; wherein the antigen recognition domain of the chimeric antigen receptor specifically binds to FCRL5; and wherein the CAR-T cell further comprises a suicide gene; wherein the suicide gene encodes a modified Human-Herpes Simplex Virus-1-thymidine kinase (TK) gene fused in-frame to the extracellular and transmembrane domains of the human CD34 cDNA. A method of treating a mammal having a cell malignancy; said method comprising administering to the mammal a plurality of disclosed chimeric antigen receptor immune effector cells.
PCT/US2023/018345 2022-04-12 2023-04-12 Chimeric antigen receptor compositions and methods of using the same WO2023200873A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263330088P 2022-04-12 2022-04-12
US63/330,088 2022-04-12

Publications (2)

Publication Number Publication Date
WO2023200873A2 WO2023200873A2 (en) 2023-10-19
WO2023200873A3 true WO2023200873A3 (en) 2023-11-23

Family

ID=88330219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/018345 WO2023200873A2 (en) 2022-04-12 2023-04-12 Chimeric antigen receptor compositions and methods of using the same

Country Status (1)

Country Link
WO (1) WO2023200873A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110189082A1 (en) * 2007-09-18 2011-08-04 Kirchner Jacqueline A Human gm-csf antigen binding proteins
US20170275362A1 (en) * 2014-12-05 2017-09-28 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
US20190389928A1 (en) * 2017-01-26 2019-12-26 Novartis Ag Cd28 compositions and methods for chimeric antigen receptor therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110189082A1 (en) * 2007-09-18 2011-08-04 Kirchner Jacqueline A Human gm-csf antigen binding proteins
US20170275362A1 (en) * 2014-12-05 2017-09-28 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
US20190389928A1 (en) * 2017-01-26 2019-12-26 Novartis Ag Cd28 compositions and methods for chimeric antigen receptor therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE PROTEIN ANONYMOUS : "anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]", XP093115363, retrieved from NCBI *
MICHAEL RETTIG, JULIE RITCHEY, PHYLLIS CHEN, JOHN F. DI PERSIO: "Control of GvHD using Novel Chimeric Suicide genes (SGs): Impact of Activation/Transduction Methods on GvHD using Informative Murine Pre-clinical Models", MOLECULAR THERAPY, ELSEVIER INC., US, vol. 3, no. 5, 5 May 2001 (2001-05-05), US , pages S108, XP009550993, ISSN: 1525-0016, DOI: 10.1006/mthe.2001.0368 *

Also Published As

Publication number Publication date
WO2023200873A2 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
Xia et al. Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
EP3904386A1 (en) Antibody and use thereof
US11692034B2 (en) CD47-CAR-T cells
WO2021152186A3 (en) Ccr8 antibodies for therapeutic applications
JP6041842B2 (en) Antibodies against human CD39 and their use for inhibiting regulatory T cell activity
TWI526223B (en) Humanized axl antibodies
JP2019525956A (en) Treatment and prevention of cytokine release syndrome using chimeric antigen receptors in combination with kinase inhibitors
TW202003037A (en) Guidance and navigation control proteins and method of making and using thereof
TW200815473A (en) Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
JPH10511085A (en) Methods for promoting an immune response using bispecific antibodies
Turini et al. A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy
JP2012126724A (en) Cytotoxic antibody directed against type b lymphoid hematopoietic proliferation
EP4039702A1 (en) Anti-b7-h3 antibody and application thereof
JP2020043848A (en) Chimeric antigen receptors, nucleic acids, plasmids and cells expressing chimeric antigen receptors, uses thereof and pharmaceutical compositions for treating cancer
CA3055438A1 (en) Multispecific antibody constructs binding to muc1 and cd3
CN108883181A (en) Inhibit TGF β in immunotherapy
CN111819203A (en) Fusion protein constructs comprising anti-MUC 1 antibody and IL-15
CN114401991A (en) anti-SIGLEC-9 compositions and methods for modulating inflammatory phenotype of myeloid cells and uses thereof
US20230270857A1 (en) Compositions including ex vivo armed t cells with multi-specific antibodies and uses thereof
US20210107996A1 (en) Plap-car-effector cells
JP2023547380A (en) Novel anti-LILRB2 antibodies and derivative products
AU2020286715A1 (en) Recombinant 4-1 BB binding proteins and their use
WO2023200873A3 (en) Chimeric antigen receptor compositions and methods of using the same
CN117425484A (en) Multifunctional immunocyte therapy
WO2021088904A1 (en) Anti-human programmed cell death ligand-1 (pd-l1) antibody and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23788910

Country of ref document: EP

Kind code of ref document: A2